Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer

作者：Legrier Marie Emmanuelle; Bieche Ivan; Gaston Julie; Beurdeley Arnaud; Yvonnet Vanessa; Deas Olivier; Thuleau Aurelie; Chateau Joubert Sophie; Servely Jean Luc; Vacher Sophie; Lassalle Myriam; Depil Stephane; Tucker Gordon C; Fontaine Jean Jacques; Poupon Marie France; Roman Roman Sergio; Judde Jean Gabriel; Decaudin Didier; Cairo Stefano^*; Marangoni Elisabetta^*

来源：British Journal of Cancer, 2016, 114(2): 177-187.

DOI：10.1038/bjc.2015.398

• STAT1
• ER-negative breast cancer
• IFN
• chemotherapy
• predictive signature

Background: Oestrogen receptor-negative (ER-) breast cancer is intrinsically sensitive to chemotherapy. However, tumour response is often incomplete, and relapse occurs with high frequency. The aim of this work was to analyse the molecular characteristics of residual tumours and early response to chemotherapy in patient-derived xenografts (PDXs) of breast cancer.
Methods: Gene and protein expression profiles were analysed in a panel of ER- breast cancer PDXs before and after chemotherapy treatment. Tumour and stromal interferon-gamma expression was measured in xenografts lysates by human and mouse cytokine arrays, respectively.
Results: The analysis of residual tumour cells in chemo-responder PDX revealed a strong overexpression of IFN-inducible genes, induced early after AC treatment and associated with increased STAT1 phosphorylation, DNA-damage and apoptosis. No increase in IFN-inducible gene expression was observed in chemo-resistant PDXs upon chemotherapy. Overexpression of IFN-related genes was associated with human IFN-gamma secretion by tumour cells.
Conclusions: Treatment-induced activation of the IFN/STAT1 pathway in tumour cells is associated with chemotherapy response in ER- breast cancer. Further validations in prospective clinical trials will aim to evaluate the usefulness of this signature to assist therapeutic strategies in the clinical setting.

• 出版日期2016-1-19